Association Between Lower Urinary Tract Symptoms and Serum Levels of Sex Hormones in Men

Urology

Volumn 72, Issue 3, 2008, Pages 552-555

  Miwa, Yoshiji ^a   Kaneda, Taisei ^a   Yokoyama, Osamu ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROLACTIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

AGE DISTRIBUTION; AGED; ANDROGEN BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ESTRADIOL BLOOD LEVEL; FOLLITROPIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LINEAR REGRESSION ANALYSIS; LOWER URINARY TRACT SYMPTOM; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL;

AGE FACTORS; AGED; DEHYDROEPIANDROSTERONE SULFATE; ERECTILE DYSFUNCTION; ESTRADIOL; FOLLICLE STIMULATING HORMONE; GONADAL STEROID HORMONES; HUMANS; LUTEINIZING HORMONE; MALE; MIDDLE AGED; PROLACTIN; PROSTATE-SPECIFIC ANTIGEN; TESTOSTERONE; UROLOGIC DISEASES;

EID: 50249116103     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.04.023     Document Type: Article

References (16)

1. Rosen R.C., Giuliano F., and Carson C.C. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 47 (2005) 824-837
2. McVary K.T. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 47 (2005) 838-845
3. Salmi S., Santti R., Gustafsson J.A., et al. Co-localization of androgen receptor with estrogen receptor beta in the lower urinary tract of the male rat. J Urol 166 (2001) 674-677
4. Liu C.C., Huanr S.P., Li W.M., et al. Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men. Urology 70 (2007) 677-680
5. Schatzl G., Brossner C., Schmid S., et al. Endocrine status in elderly men with lower urinary tract symptoms: Correlation of age, hormonal status, and lower urinary tract function. Urology 55 (2000) 397-402
6. Dharia S., and Parker Jr. C.R. Adrenal androgens and aging. Semin Reprod Med 22 (2004) 361-368
7. Kalimi M., and Regelson M. The Biologic Role of Dehydroepiandrosterone (DHEA) (1990), Walter de Gruyter, New York
8. Svec F., and Porter J.R. The actions of exogenous dehydroepiandrosterone in experimental animals and humans. Proc Soc Exp Biol Med 218 (1998) 174-191
9. Baulieu E.E., and Robel P. Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) as neuroactive neurosteroids. Proc Natl Acad Sci USA 95 (1998) 4089-4091
10. McEwen B.S., Coirini H., Westlind-Danielsson A., et al. Steroid hormones as mediators of neural plasticity. J Steroid Biochem Mol Biol 39 (1991) 223-232
11. Rupprecht R., Hauser C.A., Trapp T., et al. Neurosteroids: Molecular mechanisms of action and psychopharmacological significance. J Steroid Biochem Mol Biol 56 (1996) 163-168
12. Yokoyama O., Komatsu K., Ishiura Y., et al. Overactive bladder-Experimental aspects. Scand J Urol Nephrol Suppl 210 (2002) 59-64
13. Kanie S., Yokoyama O., Komatsu K., et al. GABAergic contribution to rat bladder hyperactivity after middle cerebral artery occlusion. Am J Physiol Regul Integr Comp Physiol 279 (2000) R1230-R1238
14. Abrams P., Cardozo L., Fall M., et al. The standardization of terminology in lower urinary tract function: Report from the Standardization Sub-committee of the International Continence Society. Neurourol Urodyn 21 (2002) 167-178
15. Hu T.W., Wagner T.H., Bentkover J.D., et al. Estimated economic costs of overactive bladder in the United States. Urology 61 (2003) 1123-1128
16. Milsom I., Abrams P., Cardozo L., et al. How widespread are the symptoms of an overactive bladder and how are they managed?. A population-based prevalence study. BJU Int 87 (2001) 760-766